ONCOMATRYX BIOPHARMA
Modulating the tumor microenvironment
Bilbao, Spain · $143.4M raised
- Headquarters
- Bilbao
- Employees
- 11–50
- Business Model
- B2B
- Total Funding
- $143.4M
- Last Round
- $67.0M Series DMar 2026
- Rounds
- 5
About
Oncomatryx Biopharma is a clinical-stage biopharmaceutical company based in Bilbao, Spain, founded to modulate the tumor microenvironment rather than attack tumor cells directly. The company is developing next-generation Antibody-Drug Conjugates that target Cancer-Associated Fibroblasts in the tumor stroma to treat difficult-to-treat metastatic solid tumors, with its lead candidate OMTX705 in clinical trials since 2022. Oncomatryx has been awarded EU EIC Accelerator funding to advance its ADC platform.
Summary
ONCOMATRYX BIOPHARMA is a Biotech company based in Bilbao, Spain. It has raised $143.4M in total across 5 rounds, most recently a $67.0M Series D round in Mar 2026. Investors include Kutxa Fundazioa, European Innovation Council Fund and Asabys Partners.
Funding History
Mar 2026
Sign up to see all 5 rounds
Venture Round through Series D — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Specialty pharmaceutical company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/oncomatryx-biopharma"><img src="https://indexed.vc/api/badge/company/oncomatryx-biopharma" alt="ONCOMATRYX BIOPHARMA on Indexed.vc" width="260" height="76" /></a>